Navigation Links
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
Date:12/17/2008

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p<0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen

Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001).

Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001)

There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worsening of pre-existing hypertension. Both doses of naproxcinod (375 and 750 mg bid) were similar to placebo, as indicated by one-sided 95% confidence intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001).

Garret FitzGerald, MD, Professor of Medicine and Pharmacology at the University of Pennsylvania School of Medicine, commented:
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1379

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
2. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
3. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
4. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
5. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
6. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
11. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... August 21, 2014 Hunhu Healthcare, ... solutions, announced today that it has entered into a ... practices, mobile technology and predictive analytics for recruiting, leveraging ... , According to Michael Emerson , co-founder and ... two patents on the technology used in what he ...
(Date:8/21/2014)... DMG Productions announces the upcoming airing of ... Monday, August 25, 2014 at 7:00 a.m. EST and ... this episode, Innovations will go behind-the-scenes to demonstrate how ... performance. Audiences will be amazed by the park's that ... and providing access to real musical instruments. , Audiences ...
(Date:8/21/2014)... Poorly-made dental restorations – whether produced in America ... health consequences for patients. To ensure better outcomes for ... and patients have a full understanding of where their ... used in the process. , Some patients believe their ... not even think twice about where their restorations are ...
(Date:8/21/2014)... Studies find that participating in a juice ... clearer skin, more energy, refresh the taste buds, help lose ... wellness center in Beverly Hills, is excited to offer guests ... their recovery room. , β€œIt’s important that we offer patients ... surgery in our Los Angeles recovery room ,” says ...
(Date:8/21/2014)... HIPAA Secure Now! rolled out its EHR (electronic ... vendors to now offer their customers a HIPAA security ... , HIPAA Secure Now! provides risk analysis services, ... U.S. The company assesses the risks of storing and ... and device used by the practice. , HIPAA ...
Breaking Medicine News(10 mins):Health News:Hunhu Healthcare Enters into Licensing Agreement with Mayo Clinic 2Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:4 Questions to Ask Before Your Next Dentist Appointment 2Health News:4 Questions to Ask Before Your Next Dentist Appointment 3Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2
... April 27 minor surgery reveals inoperable pancreatic and spinal ... Hennie Page had finally settled into a quiet life ... enjoys looking at his,paintings and frequent visits from his ... the world in years past -- leading,chartered cruises in ...
... 3 Market competition is,mounting to win the ... investigators. Field research shows that the most sought-after,clinical ... trial,invitations that they receive at their labs and ... to manage the art,and science of investigator recruitment., ...
... Grills, Photo Books and Shaving Kits Are Just a ... CVS/pharmacy,s 6,300 Convenient U.S. Locations, WOONSOCKET, R.I., June ... locations nationwide, offers,shoppers a wide selection of affordable, department ... just the right gift., "Consumers are scaling back ...
... . , Images of the inside of the intestine can ... no larger than a candy. It makes its way through the ... receiver which the patient carries on a belt. This device stores ... identify any hemorrhages or cysts. However, the camera is not very ...
... Flashpoint Medica, a full-service,healthcare advertising agency and member ... launched Flashlight Interactive, a new business unit devoted ... by agency veteran Kristen,Goelz, who joins the company ... Interactive will offer a variety of programs and,capabilities, ...
... study at the Montreal Neurological Institute at McGill University ... motor nerve cells (motor neurons) - cells that control ... a range of conditions involving nerve cell loss or ... as ALS, also known as Lou Gehrig,s disease. , ...
Cached Medicine News:Health News:Sherwood, Oregon Sailor, 78, Goes on Final Voyage 2Health News:Best Practice Toolkit Supports Recruitment of Top Clinical Investigators 2Health News:Practical Gear and Personal Gadgets: CVS/pharmacy Offers a Wide Selection of Affordable Gifts to Delight Dad This Father's Day 2Health News:Practical Gear and Personal Gadgets: CVS/pharmacy Offers a Wide Selection of Affordable Gifts to Delight Dad This Father's Day 3Health News:Magnet-controlled camera in the body 2Health News:Flashpoint Launches Flashlight Interactive, Names Kristen Goelz Head of New Division 2Health News:Finding clues for nerve cell repair 2
Inquire...
... design makes positioning quick and ... wheelchair accessible and can support ... lbs. The AIT-8B provides stable ... units and includes a motorized ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... FDA-Approved BV-1000 is the worlds ... system. With the BV-1000, Topcon ... of refracting instruments. This innovative ... binocular auto-refractor, auto-keratometer, automatic chart ...
Medicine Products: